On May 30, 2025, BioLineRx Ltd. announced new data from the single-arm pilot phase of the CheMo4METPANC Phase 2 combination trial of motixafortide in first-line pancreatic cancer (PDAC) was presented at the 2025 ASCO Annual Meeting. The trial evaluated motixafortide in combination with cemiplimab and standard chemotherapy.
Updated results from the pilot phase (N=11) demonstrated an overall response rate (ORR) of 64% (7/11) and a disease control rate (DCR) of 91% (10/11). These figures significantly exceed historical ORR and DCR benchmarks of 23% and 48%, respectively, for standard chemotherapy alone.
Four of eleven patients remained progression-free for over one year, and two patients achieved definitive treatment for metastatic PDAC, including one with complete resolution of liver lesions and another with a complete pathological response after surgery. An analysis of biopsies also revealed a significant increase in CD8+ T-cell tumor infiltration across all treated patients, supporting the mechanism of overcoming immunosuppression. Based on these results, the Phase 2 trial was amended to become a randomized study, increasing planned enrollment from 30 to 108 patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.